AA
TEVA icon

AlphaMark Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

AlphaMark Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-750
Closed -$12K – 809
2024
Q2 		$12K Hold
750
– – ﹤0.01% 510
2024
Q1 		$11K Hold
750
– – ﹤0.01% 524
2023
Q4 		$8K Hold
750
– – ﹤0.01% 555
2023
Q3 		$8K Hold
750
– – ﹤0.01% 544
2023
Q2 		$6K Hold
750
– – ﹤0.01% 475
2023
Q1 		$7K Hold
750
– – ﹤0.01% 466
2022
Q4 		$7K Hold
750
– – ﹤0.01% 430
2022
Q3 		$6K Hold
750
– – ﹤0.01% 484
2022
Q2 		$6K Hold
750
– – ﹤0.01% 454
2022
Q1 		$7K Hold
750
– – ﹤0.01% 442
2021
Q4 		$6K Buy
+750
New +$6.77K ﹤0.01% 441
2019
Q1 		– Sell
-1,575
Closed -$24K – 516
2018
Q4 		$24K Buy
+1,575
New +$32.3K 0.01% 236

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

AlphaMark Advisors's TEVA Position: Q3 2024 in Review

AlphaMark Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2024, closing a stake of 750 shares — an estimated $12K sold.

AlphaMark Advisors first reported a position in TEVA in Q4 2018 and held it in 12 quarters. The position peaked at $24K in Q4 2018. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • AlphaMark Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2024 after selling out during the quarter.
  • AlphaMark Advisors sold 750 Teva Pharmaceutical Industries Limited shares in Q3 2024, an estimated $12K.
  • AlphaMark Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2018 and held it in 12 quarters.
  • AlphaMark Advisors's Teva Pharmaceutical Industries Limited position peaked at $24K in Q4 2018.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2024.

Based on AlphaMark Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.